Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia (Q38853220)

7 September 2017

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia (English)

1 reference

7 September 2017

1 reference

6

1 reference

7 September 2017

I-K Park

1

1 reference

7 September 2017

B Mundy-Bosse

2

1 reference

7 September 2017

S P Whitman

3

1 reference

7 September 2017

X Zhang

4

1 reference

7 September 2017

S L Warner

5

1 reference

7 September 2017

W Blum

7

1 reference

7 September 2017

G Marcucci

8

1 reference

7 September 2017

M A Caligiuri

9

1 reference

7 September 2017

19 June 2015

1 reference

7 September 2017

1 reference

7 September 2017

29

1 reference

7 September 2017

2382-2389

1 reference

7 September 2017

12

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2015.147

7 September 2017

0 references

cites work

FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

FLT3 inhibition in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

FLT3 as a therapeutic target in AML: still challenging after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor alpha-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Tyro-3 family receptors are essential regulators of mammalian spermatogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

TAM receptors are pleiotropic inhibitors of the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

AXL is an essential factor and therapeutic target for metastatic ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Coexpression of growth arrest-specific gene 6 and receptor tyrosine kinases Axl and Sky in human uterine endometrial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Simultaneous evaluation of viability and Bcl-2 in small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Micro RNAs as a new therapeutic target towards leukaemia signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

Axl-dependent signalling: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.147

First Axl inhibitor enters clinical trials

21 January 2018

1 reference

12 December 2020

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

1 reference

12 December 2020

Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis

1 reference

12 December 2020

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2015.147

1 reference

Dimensions Publication ID

7 September 2017

0 references

1 reference